Next Article in Journal
Calebin A, a Compound of Turmeric, Down-Regulates Inflammation in Tenocytes by NF-κB/Scleraxis Signaling
Next Article in Special Issue
mTOR Signaling Components in Tumor Mechanobiology
Previous Article in Journal
Modified Histone Peptides Linked to Magnetic Beads Reduce Binding Specificity
Previous Article in Special Issue
Tadalafil Treatment of Mice with Fetal Growth Restriction and Preeclampsia Improves Placental mTOR Signaling
 
 
Review

Predominant Role of mTOR Signaling in Skin Diseases with Therapeutic Potential

1
National Center of Rare Diseases—Cutaneous Lymphoma, Second Department of Dermatology and Venereal Diseases, Attikon University General Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece
2
Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
*
Author to whom correspondence should be addressed.
Academic Editor: Irmgard Tegeder
Int. J. Mol. Sci. 2022, 23(3), 1693; https://doi.org/10.3390/ijms23031693
Received: 28 December 2021 / Revised: 30 January 2022 / Accepted: 31 January 2022 / Published: 1 February 2022
(This article belongs to the Special Issue Frontiers in mTOR Signaling)
The serine/threonine kinase mechanistic target of rapamycin (mTOR) plays a pivotal role in the regulation of cell proliferation, survival, and motility in response to availability of energy and nutrients as well as mitogens. The mTOR signaling axis regulates important biological processes, including cellular growth, metabolism, and survival in many tissues. In the skin, dysregulation of PI3K/AKT/mTOR pathway may lead to severe pathological conditions characterized by uncontrolled proliferation and inflammation, including skin hyperproliferative as well as malignant diseases. Herein, we provide an update on the current knowledge regarding the pathogenic implication of the mTOR pathway in skin diseases with inflammatory features (such as psoriasis, atopic dermatitis, pemphigus, and acne) and malignant characteristics (such as cutaneous T cell lymphoma and melanoma) while we critically discuss current and future perspectives for therapeutic targeting of mTOR axis in clinical practice. View Full-Text
Keywords: mTOR signaling pathway; psoriasis; atopic dermatitis; pemphigus; acne; cutaneous T cell lymphoma; melanoma; inhibitors; therapy mTOR signaling pathway; psoriasis; atopic dermatitis; pemphigus; acne; cutaneous T cell lymphoma; melanoma; inhibitors; therapy
Show Figures

Figure 1

MDPI and ACS Style

Karagianni, F.; Pavlidis, A.; Malakou, L.S.; Piperi, C.; Papadavid, E. Predominant Role of mTOR Signaling in Skin Diseases with Therapeutic Potential. Int. J. Mol. Sci. 2022, 23, 1693. https://doi.org/10.3390/ijms23031693

AMA Style

Karagianni F, Pavlidis A, Malakou LS, Piperi C, Papadavid E. Predominant Role of mTOR Signaling in Skin Diseases with Therapeutic Potential. International Journal of Molecular Sciences. 2022; 23(3):1693. https://doi.org/10.3390/ijms23031693

Chicago/Turabian Style

Karagianni, Fani, Antreas Pavlidis, Lina S. Malakou, Christina Piperi, and Evangelia Papadavid. 2022. "Predominant Role of mTOR Signaling in Skin Diseases with Therapeutic Potential" International Journal of Molecular Sciences 23, no. 3: 1693. https://doi.org/10.3390/ijms23031693

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop